Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index; none of the 20 sources its claims cite is checked for support yet.

Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study

Open access
Sands, Jacob, Ahn, Myung-Ju, Lisberg, Aaron, Cho, Byoung Chul, Blumenschein, George, Shum, Elaine, Pons Tostivint, Elvire, Goto, Yasushi, Yoh, Kiyotaka, Heist, Rebecca, Shimizu, Junichi, Lee, Jong-Seok, Baas, Paul, Planchard, David, Pérol, Maurice, Felip, Enriqueta, Su, Wu-Chou, Zebger-Gong, Hong, Lan, Lan, Liu, Chelsea, Howarth, Paul, Chiaverelli, Rachel, Paz-Ares, Luis·2025·Journal of Clinical Oncology

Abstract

PURPOSE: Datopotamab deruxtecan (Dato-DXd) is a trophoblast cell-surface antigen-2–directed antibody-drug conjugate with a highly potent topoisomerase I inhibitor payload. The TROPION-Lung05 phase II trial (ClinicalTrials.gov identifier: NCT04484142 ) evaluated the safety and clinical activity of Dato-DXd in patients with advanced/metastatic non–small cell lung cancer (NSCLC) with actionable genomic alterations progressing on or after targeted therapy and platinum-based chemotherapy. PATIENTS AND METHODS: Patients received Dato-DXd 6 mg/kg once every 3 weeks. The primary end point was objective response rate (ORR) by blinded independent central review. Secondary end points included duration of response (DOR), safety, tolerability, and survival. RESULTS: Among 137 patients who received at least 1 dose of Dato-DXd, 71.5% received at least three lines of prior therapies for advanced/metastatic disease. Overall, 56.9% had EGFR mutations and 24.8% had ALK rearrangements. Median treatment duration was 4.4 months (range, 0.7-20.6). The confirmed ORR was 35.8% (95% CI, 27.8 to 44.4) overall, and 43.6% (95% CI, 32.4 to 55.3) and 23.5% (95% CI, 10.7 to 41.2) in those with EGFR mutations and ALK rearrangements, respectively. The median DOR was 7.0 months (95% CI, 4.2 to 9.8), and the overall disease control rate was 78.8% (95% CI, 71.0 to 85.3). Grade ≥3 treatment-related adverse events (TRAEs) occurred in 28.5% of patients. The most common TRAE was stomatitis (preferred term; any grade: 56.2%; grade ≥3: 9.5%). Five (3.6%) patients experienced adjudicated treatment-related interstitial lung disease/pneumonitis, with 1 (0.7%) grade 5 event. CONCLUSION: Encouraging and durable antitumor activity was observed with Dato-DXd in this heavily pretreated advanced/metastatic NSCLC population with actionable genomic alterations. The rate of treatment-related grade ≥3 toxicities was comparable with previous observations, and no new safety signals were observed.

Overview

CoChat Summary

## TL;DR

This phase II single-arm study found that datopotamab deruxtecan (Dato-DXd) had clinically meaningful activity in heavily pretreated advanced/metastatic NSCLC with actionable genomic alterations, with a confirmed objective response rate (ORR) of 35.8% overall. Safety was manageable, though oral mucositis/stomatitis was common and adjudicated treatment-related ILD/pneumonitis occurred in 5 patients (3.6%), including 1 death.

## Key findings

  • Among 137 treated patients, the confirmed ORR was 35.8% (95% CI, 27.8 to 44.4), including 4 complete responses (2.9%) and 45 partial responses (32.8%).
  • Disease control rate was 78.8% (95% CI, 71.0 to 85.3); median duration of response was 7.0 months (95% CI, 4.2 to 9.8), median progression-free survival was 5.4 months (95% CI, 4.7 to 7.0), and median overall survival was 13.6 months (95% CI, 9.9 to not evaluable).
  • In the EGFR-mutated subgroup (n = 78), ORR was 43.6% (95% CI, 32.4 to 55.3), with all four complete responders in the study coming from this subgroup; among those with sensitizing or T790M mutations previously treated with osimertinib, ORR was 49.1% (95% CI, 35.4 to 62.9).
  • In the ALK-rearranged subgroup (n = 34), ORR was 23.5% (95% CI, 10.7 to 41.2), median DOR was 7.0 months (95% CI, 2.8 to 8.4), and median OS was 9.3 months (95% CI, 5.8 to 18.3).

## Methods

  • Design: Phase II, global, single-arm, open-label study (TROPION-Lung05; NCT04484142) of Dato-DXd in advanced/metastatic NSCLC with actionable genomic alterations after progression on targeted therapy and platinum-based chemotherapy.
  • Sample/data: 137 adults treated between March 29, 2021, and December 14, 2022; required actionable alterations included EGFR, ALK, ROS1, NTRK, BRAF, MET exon 14 skipping, or RET. Patients had measurable disease and ECOG performance status 0 or 1.
  • Analysis: Primary endpoint was ORR by blinded independent central review per RECIST v1.1; DOR, DCR, PFS, OS, and safety were secondary endpoints. ORR used Clopper-Pearson exact CIs; time-to-event outcomes used Kaplan-Meier methods.

## Limitations

  • The study was single-arm and open-label, so there was no randomized control group for direct comparative efficacy assessment; this is stated by the study design and is evident from the text.
  • The paper notes that comparative assessment is complicated because post-progression treatment histories, especially after osimertinib and chemotherapy, are limited and heterogeneous; this is stated in the discussion.
  • The analysis reports subgroup findings for small numbers in some alteration groups beyond EGFR and ALK, but those subgroup results are not detailed in the main text; this is evident from the text.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1200/jco-24-01349

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

FIG 1. Patient disposition. aPatients who signed the informed consent form and who were screened for eligibility. AE, adverse event.
FIG 1. Patient disposition. aPatients who signed the informed consent form and who were screened for eligibility. AE, adverse event.CC BY-NC-ND · PubMed Central
FIG 2. Antitumor activity of Dato-DXd in the overall cohort. (A) Waterfall plot of best percentage change in the SOD from baseline by BICR (n = 126). Snapshot data cutoff, December 14, 2022. Below the waterfall plot, categories of genomic alterations before treatment with Dato-DXd are identified for each patient. (B) Percentage change from baseline in SOD in target lesions in patients with a confirmed CR/PR (upper panel) or SD (lower panel) by BICR. aExon 19 deletion (Ex19Del) or Exon 21 L858R (Ex21 L858R). bIncludes Exon 18 G719 (Ex18 G719), Exon 19 insertion (Ex19 Ins), Exon 20 insertion (Ex20 Ins), Exon 20 S768I (Ex 20 S768I), Exon 21 L861G (Ex 21 L861G), V323I p.1759M, G724S, and unknown EGFRm. BICR, blinded independent central review; CR, complete response; Dato-DXd, datopotamab deruxtecan; EGFRm, EGFR mutation; NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable disease; SOD, sum of the diameters.
FIG 2. Antitumor activity of Dato-DXd in the overall cohort. (A) Waterfall plot of best percentage change in the SOD from baseline by BICR (n = 126). Snapshot data cutoff, December 14, 2022. Below the waterfall plot, categories of genomic alterations before treatment with Dato-DXd are identified for each patient. (B) Percentage change from baseline in SOD in target lesions in patients with a confirmed CR/PR (upper panel) or SD (lower panel) by BICR. aExon 19 deletion (Ex19Del) or Exon 21 L858R (Ex21 L858R). bIncludes Exon 18 G719 (Ex18 G719), Exon 19 insertion (Ex19 Ins), Exon 20 insertion (Ex20 Ins), Exon 20 S768I (Ex 20 S768I), Exon 21 L861G (Ex 21 L861G), V323I p.1759M, G724S, and unknown EGFRm. BICR, blinded independent central review; CR, complete response; Dato-DXd, datopotamab deruxtecan; EGFRm, EGFR mutation; NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable disease; SOD, sum of the diameters.CC BY-NC-ND · PubMed Central
FIG 3. Kaplan-Meier estimates of survival. (A) PFS by BICR per RECIST v1.1. (B) OS. BICR, blinded independent central review; NE, not evaluable; OS, overall survival; PFS, progression-free survival.
FIG 3. Kaplan-Meier estimates of survival. (A) PFS by BICR per RECIST v1.1. (B) OS. BICR, blinded independent central review; NE, not evaluable; OS, overall survival; PFS, progression-free survival.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 14 Not checked · 54 Own results and interpretations

32 more claims

Create a free account to see all 68 claims and to verify the 20 references still open.

See all claims — free account
  • Probably not a substantial claim. 22
  • It may state two separate claims as one. 16

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 34 references

Cited by

See all 130

Metadata

Authors
Sands, J., Ahn, M.-J., Lisberg, A., Cho, B. C., Blumenschein, G., Shum, E., Pons Tostivint, E., Goto, Y., Yoh, K., Heist, R., Shimizu, J., Lee, J.-S., Baas, P., Planchard, D., Pérol, M., Felip, E., Su, W.-C., Zebger-Gong, H., Lan, L., Liu, C., Howarth, P., Chiaverelli, R., & Paz-Ares, L.
Affiliations
  • Dana-Farber Cancer Institute (US)
  • Dana-Farber Cancer Institute, Boston, MA
  • National Cancer Center Hospital East (JP)
  • Harvard University (US)
  • Aichi Cancer Center (JP)
  • Seoul National University Bundang Hospital (KR)
  • Daiichi Sankyo Europe GmbH, Munich, Germany
  • Daiichi Sankyo (United States) (US)
Corresponding author
  • Heist, Rebecca
  • Lee, Jong-Seok
  • Lan, Lan
  • Liu, Chelsea
  • Howarth, Paul
  • Chiaverelli, Rachel
Venue
Journal of Clinical Oncology
Published
2025-04
Volume
43
Issue
10
Pages
1254-1265
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W4406090459
Cited by
130
References
34
Citations by year
2026: 77 · 2025: 53
FWCI
84.85
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Journal of Clinical Oncology (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Leiden Repository (Leiden University) (submittedVersion, cc-by-nc-nd)
Funders
Daiichi Sankyo Europe
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords
datopotamab deruxtecan, trophoblast cell surface antigen 2, antibody-drug conjugates, topoisomerase I inhibitor, non-small cell lung cancer, actionable genomic alterations, EGFR mutation, ALK rearrangement, objective response rate, duration of response, stomatitis, interstitial lung disease, treatment-related adverse events
MeSH terms
Adult, Aged, Aged, 80 and over, Camptothecin, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Immunoconjugates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study. https://app.cochat.ai/papers/10.1200/jco-24-01349
The paper
Sands, J., Ahn, M.-J., Lisberg, A., Cho, B. C., Blumenschein, G., Shum, E., Pons Tostivint, E., Goto, Y., Yoh, K., Heist, R., Shimizu, J., Lee, J.-S., Baas, P., Planchard, D., Pérol, M., Felip, E., Su, W.-C., Zebger-Gong, H., Lan, L., . . . Paz-Ares, L. (2025). Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco-24-01349

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.